Delayed contrast extravasation MRI: a new paradigm in neuro-oncology. (30th November 2014)
- Record Type:
- Journal Article
- Title:
- Delayed contrast extravasation MRI: a new paradigm in neuro-oncology. (30th November 2014)
- Main Title:
- Delayed contrast extravasation MRI: a new paradigm in neuro-oncology
- Authors:
- Zach, Leor
Guez, David
Last, David
Daniels, Dianne
Grober, Yuval
Nissim, Ouzi
Hoffmann, Chen
Nass, Dvora
Talianski, Alisa
Spiegelmann, Roberto
Tsarfaty, Galia
Salomon, Sharona
Hadani, Moshe
Kanner, Andrew
Blumenthal, Deborah T.
Bukstein, Felix
Yalon, Michal
Zauberman, Jacob
Roth, Jonathan
Shoshan, Yigal
Fridman, Evgeniya
Wygoda, Marc
Limon, Dror
Tzuk, Tzahala
Cohen, Zvi R.
Mardor, Yael - Abstract:
- Abstract: Background: Conventional magnetic resonance imaging (MRI) is unable to differentiate tumor/nontumor enhancing tissues. We have applied delayed-contrast MRI for calculating high resolution treatment response assessment maps (TRAMs) clearly differentiating tumor/nontumor tissues in brain tumor patients. Methods: One hundred and fifty patients with primary/metastatic tumors were recruited and scanned by delayed-contrast MRI and perfusion MRI. Of those, 47 patients underwent resection during their participation in the study. Region of interest/threshold analysis was performed on the TRAMs and on relative cerebral blood volume maps, and correlation with histology was studied. Relative cerebral blood volume was also assessed by the study neuroradiologist. Results: Histological validation confirmed that regions of contrast agent clearance in the TRAMs >1 h post contrast injection represent active tumor, while regions of contrast accumulation represent nontumor tissues with 100% sensitivity and 92% positive predictive value to active tumor. Significant correlation was found between tumor burden in the TRAMs and histology in a subgroup of lesions resected en bloc ( r 2 = 0.90, P < .0001). Relative cerebral blood volume yielded sensitivity/positive predictive values of 51%/96% and there was no correlation with tumor burden. The feasibility of applying the TRAMs for differentiating progression from treatment effects, depicting tumor within hemorrhages, and detecting residualAbstract: Background: Conventional magnetic resonance imaging (MRI) is unable to differentiate tumor/nontumor enhancing tissues. We have applied delayed-contrast MRI for calculating high resolution treatment response assessment maps (TRAMs) clearly differentiating tumor/nontumor tissues in brain tumor patients. Methods: One hundred and fifty patients with primary/metastatic tumors were recruited and scanned by delayed-contrast MRI and perfusion MRI. Of those, 47 patients underwent resection during their participation in the study. Region of interest/threshold analysis was performed on the TRAMs and on relative cerebral blood volume maps, and correlation with histology was studied. Relative cerebral blood volume was also assessed by the study neuroradiologist. Results: Histological validation confirmed that regions of contrast agent clearance in the TRAMs >1 h post contrast injection represent active tumor, while regions of contrast accumulation represent nontumor tissues with 100% sensitivity and 92% positive predictive value to active tumor. Significant correlation was found between tumor burden in the TRAMs and histology in a subgroup of lesions resected en bloc ( r 2 = 0.90, P < .0001). Relative cerebral blood volume yielded sensitivity/positive predictive values of 51%/96% and there was no correlation with tumor burden. The feasibility of applying the TRAMs for differentiating progression from treatment effects, depicting tumor within hemorrhages, and detecting residual tumor postsurgery is demonstrated. Conclusions: The TRAMs present a novel model-independent approach providing efficient separation between tumor/nontumor tissues by adding a short MRI scan >1 h post contrast injection. The methodology uses robust acquisition sequences, providing high resolution and easy to interpret maps with minimal sensitivity to susceptibility artifacts. The presented results provide histological validation of the TRAMs and demonstrate their potential contribution to the management of brain tumor patients. … (more)
- Is Part Of:
- Neuro-oncology. Volume 17(2015)Supplement 3
- Journal:
- Neuro-oncology
- Issue:
- Volume 17(2015)Supplement 3
- Issue Display:
- Volume 17, Issue 3 (2015)
- Year:
- 2015
- Volume:
- 17
- Issue:
- 3
- Issue Sort Value:
- 2015-0017-0003-0000
- Page Start:
- 457
- Page End:
- 465
- Publication Date:
- 2014-11-30
- Subjects:
- brain metastases -- brain tumor -- delayed-contrast MRI -- pseudoprogression -- radiation necrosis
Brain Neoplasms -- Periodicals
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481 - Journal URLs:
- http://neuro-oncology.dukejournals.org/ ↗
http://neuro-oncology.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/content?genre=journal&issn=1522-8517 ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/neuonc/nou230 ↗
- Languages:
- English
- ISSNs:
- 1522-8517
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.288000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25130.xml